At present it is estimated that 25% of the population older than 85 years have significant cognitive impairment. The global prevalence of cognitive impairment and dementia including Alzheimer’s disease is expected to rise significantly in proportion to increased life expectancy. Deterioration of memory function and ultimately establishment of Alzheimer’s disease (AD) severely debilitates the affected individual, uncompromisingly decreasing the quality of life of both affected patients and their care givers. Moreover, the cost of providing adequate care to patients with AD is a significant burden to both family and the health care providers. Therefore, various attempts have been made to identify means of either delaying the onset of cognitive impairment or improving memory function in patients affected by AD. Among a number of participants, importance of dietary fatty acids in particular omega-3 based fatty acids have gained significant momentum. This article aims to review published evidences for the role of omega-3 in memory function.
Naderali EKObesity and cardiovascular dysfunction: a role for resveratrol? ObesRes Clin Pract.2009;3(1):45-52.
3.
Weih W., Wiltfang J., Kornhuber J.Non-pharmacologic prevention of Alzheimer’s disease: nutritional and life-style risk factors. J Neural Transm. 2007;114(9):1187-1197.
4.
Forsyth E., Ritzline PDAn overview of the etiology, diagnosis, and treatment of Alzheimer disease . Phys Ther. 1998;78(12): 1325-1331.
5.
Albanese E., Banerjee S., Dhanasiri S., et al. Dementia UKA report to the Alzheimer’s Society on the prevalence and economic cost of dementia in the UK produced by King’s College London and London School of Economics. London, UK: Alzheimer’s Society; 2007.
6.
McLean CA , Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease . Ann Neurol. 1999;46(6):860-866.
7.
Chui DH, Tanahashi H., Ozawa K., et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med . 1999; 5(5):560-564.
8.
Evin G., Weidemann A.Biogenesis and metabolism of Alzheimer’s disease Abeta amyloid peptides . Peptides. 2002;23(7): 1285-1297.
9.
Barghorn S., Nimmrich V., Striebinger A., et al. Globular amyloid beta-peptide oligomer: a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem. 2005;95(3):834-847.
10.
Lacor PN, Buniel MC, Furlow PW, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci. 2007;27(4):796-807.
11.
Naderali EK, Ratcliffe SH, Dale MCObesity and Alzheimer’s disease: a link between body weight and cognitive function in old age. Am J Alzheimers Dis Other Demen.2009;24(6):445-449.
12.
Gustaw-Rothenberg K.Dietary patterns associated with Alzheimer’s disease: population based study. Int J Environ Res Public Health. 2009;6(4):1335-1340.
Barberger-Gateau P., Raffaitin C., Letenneur L., et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology. 2007 ;69(20):1921-1930.
15.
Scarmeas N. , Luchsinger JA, Schupf N., et al. Physical activity, diet, and risk of Alzheimer disease. JAMA.2009;302(6):627-637.
16.
Scarmeas N. , Stern Y., Mayeux R., Luchsinger JAMediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol. 2006;63(12):1709-1717.
17.
Florent-Bechard S., Desbene C., Garcia P., et al. The essential role of lipids in Alzheimer’s disease. Biochimie.2009;91(6):804-809.
18.
Youssef I., Florent-Bechard S., Malaplate-Armand C., et al. N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. Neurobiol Aging. 2008 ;29(9):1319-1333.
19.
Calder PCPolyunsaturated fatty acids, inflammation, and immunity. Lipids. 2001;36(9):1007-1024.
20.
Vedin I., Cederholm T., Freund-Levi Y., et al. Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study . J Lipid Res. 2010;51(5):1179-1185.
21.
Robinson JG , Ijioma N., Harris W.Omega-3 fatty acids and cognitive function in women. Womens Health (Lond Engl). 2010;6(1): 119-134.
22.
Wurtman RJ, Ulus IH, Cansev M., Watkins CJ, Wang L., Marzloff G.Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res. 2006;1088(1):83-92.
23.
Wurtman RJ, Cansev M., Sakamoto T., Ulus IHUse of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr. 2009; 29:59-87.
24.
Arendash GW , Jensen MT, Salem N. Jr, et al. A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer’s transgenic mice. Neuroscience. 2007; 149(2):286-302.
25.
Chiu CC, Su KP, Cheng TC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomised double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry . 2008;32(6):1538-1544.
26.
Freund-Levi Y., Eriksdotter-Jönhagen M., Cederholm T., et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol . 2006;63(10):1402-1428.
27.
Kröger E., Verreault R., Carmichael PH, et al. Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am J Clin Nutr.2009;90(1):184-192.
28.
Devore EE, Grodstein F., van Rooij FJ, et al. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr.2009 ;90(1):170-176.
29.
Samieri C., Féart C., Letenneur L., et al. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr . 2008;88(3):714-721.
30.
Calon F., Cole G.Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot Essent Fatty Acids. 2007;77(5-6):287-293.
31.
Mitchell DC , Gawrisch K., Litman BJ, Salem N Jr.. Why is docosahexaenoic acid essential for nervous system function? Biochem Soc Trans. 1998;26(3):365-370.
32.
Kim HY, Akbar M., Kim YSPhosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids.2010;82(4-6):165-172.
33.
Prasad MR, Lovell MA, Yatin M., Dhillon H., Markesbery WRRegional membrane phospholipid alterations in Alzheimer’s disease. Neurochem Res. 1998;23(1):81-88.
34.
Soderberg M. , Edlund C., Kristensson K., Dallner G.Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease. Lipids. 1991;26(6):421-425.
35.
Yurko-Mauro K.Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline. Curr Alzheimer Res. 2010;7(3):190-196.
36.
Fotuhi M., Mohassel P., Yaffe K.Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol.2009;5(3):140-152.
37.
Calon F., Lim GP, Yang F., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron. 2004;43(5):633-645.
38.
Lim GP, Calon F., Morihara T., et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci. 2005;25(12): 3032-3040.
39.
Mucke L., Masliah E., Yu GQ, et al. High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20(11):4050-4058.
40.
Florent S., Malaplate-Armand C., Youssef I., et al. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J Neurochem. 2006;96(2):385-395.
41.
Liu L., Komatsu H., Murray IV, Axelsen PHPromotion of amyloid beta protein misfolding and fibrillogenesis by a lipid oxidation product. J Mol Biol. 2008;377(4):1236-1250.
